Detalles de la búsqueda
1.
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase.
Immunity
; 57(3): 587-599.e4, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38395697
2.
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
Nature
; 602(7898): 682-688, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35016197
3.
Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections.
J Infect Dis
; 228(5): 564-575, 2023 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37104046
4.
SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.
Cell Rep Med
; 5(3): 101474, 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38508136
5.
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.
bioRxiv
; 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38464151
6.
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Mult Scler Relat Disord
; 70: 104486, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36628884
7.
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.
Sci Transl Med
; 15(683): eabo2847, 2023 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36791207
8.
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
Vaccine
; 40(42): 6114-6124, 2022 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36115801
9.
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
medRxiv
; 2022 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35734083
10.
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
Vaccine
; 40(26): 3621-3632, 2022 06 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35577631
11.
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.
EClinicalMedicine
; 45: 101323, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35284808
12.
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats.
Front Immunol
; 12: 791764, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34868082
13.
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.
medRxiv
; 2021 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34580673
14.
Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer.
Cancer Cell
; 40(6): 575-577, 2022 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35504289
Resultados
1 -
14
de 14
1
Próxima >
>>